<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797706</url>
  </required_header>
  <id_info>
    <org_study_id>CS-201</org_study_id>
    <secondary_id>EudraCT No. 2007-002695-34</secondary_id>
    <nct_id>NCT00797706</nct_id>
  </id_info>
  <brief_title>Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers</brief_title>
  <official_title>A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kringle Pharma Europe AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kringle Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kringle Pharma Europe AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the investigational medicinal product CHRONSEAL
      intended for future treatment of chronic venous leg ulcers is safe and tolerated and if it
      has an ulcer size reduction effect when administered to individuals suffering from venous leg
      ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate safety and local tolerance of CHRONSEAL® cream containing 2 different concentrations of API, applied at 3 occasions every second day in chronic venous leg ulcers compared to vehicle.</measure>
    <time_frame>From start of treatment to 12 weeks post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the treatment effect on ulcer area reduction and changes of ulcer condition of CHRONSEAL® cream, containing 2 different concentrations API, applied at 3 occasions every second day in chronic venous leg ulcers compared to vehicle.</measure>
    <time_frame>From start of treatment to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Chronic Venous Leg Ulcers</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHRONSEAL</intervention_name>
    <description>Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions</description>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (Run-in period):

          1. Caucasian male or clinically sterile female subjects

          2. 40 years or older.

          3. Ankle brachial index of at least 0.6.

          4. Written informed consent obtained.

          5. Subject legally competent and able to communicate effectively.

          6. Subject likely to co-operate.

          7. Uncomplicated venous ulcer as by clinical diagnosis.

          8. Full skin ulcer.

          9. Localisation above the foot and below the knee (wrist and malleoli included)

         10. Duration of at least 3 months.

         11. Area 3-20 cm2.

        Exclusion criteria (Run-in period)

          1. Visible signs of infection, black necrosis or discharge in the target ulcer.

          2. More than ~20% slough after debridement.

          3. Ulcer that by location or extension will either be difficult to follow or to treat
             according to the protocol.

          4. Other known etiology of the target ulcer.

          5. Subject having to the discretion of the investigator clinically significant findings
             on physical examination or vital signs.

          6. Concomitant systemic or topical treatment within 14 days prior to start of study
             medication with antibiotics or antiseptics for treatment of ulcer infection in target
             ulcer.

          7. Concomitant systemic treatment within 14 days prior to start of study medication with
             immunosuppressives

          8. Concomitant topical treatment within 14 days prior to start of study medication with
             any of the following:

               -  NSAIDs, aspirin

               -  Growth factors, or other biologically active agents

               -  Products containing chlorhexidine, potassium permanganate, iodine or silver

          9. Diabetes Mellitus requiring pharmaceutical treatment.

         10. Co-morbidity with a life expectancy less than 6 months.

         11. Co-morbidity expected to lower compliance.

         12. Diagnosed kidney disease

         13. Individuals sensitive to any of the study medication components.

         14. Subject having received an investigational drug product, or been enrolled in other
             investigational drug protocols within a period of 30 days prior to receiving the first
             dose of the study medication.

         15. Known abuse of alcohol, drugs or pharmaceuticals.

         16. Diagnosis of squamous epithelia carcinoma

         17. Diagnoses of a serious psychiatric illness which may influence study participation.

        Inclusion criteria (Randomization)

          1. Subject likely to co-operate.

          2. Ulcer area reduction less than 50% during run-in period.

          3. Ulcer area 3-20 cm2.

        Exclusion criteria (Randomization)

        1.&amp; 2. = Run-in period criteria 1. &amp; 2.

        3. Subject having to the discretion of the investigator clinically significant findings on
        vital signs or laboratory values.

        4.-10. = Run-in period criteria 6., 7., 8., 11., 12., 13., &amp; 14
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Olav Høivik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medi 3 Innlandet AS, avd Hamar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Andersson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Halland County Council, Department of Dermatology and Infectious diseases, Halmstad, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Apelqvist, Assoc. Prof., PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Endocrinology, University Hospital Malmö,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medi3 Innlandet AS, Department Elverum</name>
      <address>
        <city>Elverum</city>
        <zip>2402</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudavdelingen Helse</name>
      <address>
        <city>Førde</city>
        <zip>6807</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi 3 Innlandet AS, Department Hamar</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colosseumklinikken</name>
      <address>
        <city>Oslo</city>
        <zip>0369</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vårdcentralen Alvesta</name>
      <address>
        <city>Alvesta</city>
        <zip>342 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus AB</name>
      <address>
        <city>Danderyd</city>
        <zip>SE-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carema Vårdcentral Gubbängen</name>
      <address>
        <city>Enskede</city>
        <zip>SE-122 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology and Infectious diseases</name>
      <address>
        <city>Halmstad</city>
        <zip>SE-301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Husläkarna i Kungsbacka</name>
      <address>
        <city>Kungsbacka</city>
        <zip>SE-434 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Lund University hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital MAS</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gamla Stans Vårdcentral</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-111 29</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taptogatans Husläkare</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-115 26</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Norrlands University hospital</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Sciences, Section of Dermatology and Venereology, Uppsala University hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 05</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neptunuskliniken</name>
      <address>
        <city>Varberg</city>
        <zip>SE-432 44</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>February 4, 2010</last_update_submitted>
  <last_update_submitted_qc>February 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Anders Vahlne/CEO</name_title>
    <organization>Kringle Pharma Europe AB</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

